Epstein–Barr virus-associated lymphomas

References

• Hennessy K, Kieff E. One of two Epstein-Barr virus nuclear antigens contains a glycine-alanine copolymer domain. Proc. Natl Acad. Sci. USA 80, 5665–5669 (1983).
   PubMedGoogle Scholar
• Moore KW, Vieira P, Fiorentino DF, Trounstine ML, Khan TA, Mosmann TR. Homology of cytokine synthesis inhibitory factor (IL-10) to the Epstein-Barr virus gene BCRFI. Science 248, 1230–1234 (1990).
   PubMed Web of Science ®Google Scholar
• Young LS, Rickinson AB. Epstein-Barr virus: 40 years on. Nature Rev. Cancer 4, 757–768 (2004).
   PubMed Web of Science ®Google Scholar
• Thorley-Lawson DA, Gross A. Persistence of the Epstein-Barr virus and the origins of associated lymphomas. N. Engl. J. Med. 350, 1328–1337 (2004).
   PubMed Web of Science ®Google Scholar
• Young LS, Dawson CW, Eliopoulos AG. The expression and function of Epstein-Barr virus encoded latent genes. Mol. Pathol. 53, 238–247 (2000).
   PubMedGoogle Scholar
• Khanna R, Moss D, Gandhi MK. Applications of emerging immunotherapeutic strategies for Epstein-Barr virus-associated malignancies. Nature Clin. Pract. Oncol. 2, 138–149 (2005).
   PubMedGoogle Scholar
• Miyashita EM, Yang B, Babcock GJ, Thorley-Lawson DA. Identification of the site of Epstein-Barr virus persistence in vivo as a resting B cell. J. Virol. 71, 4882–4891 (1997).
   PubMed Web of Science ®Google Scholar
• Okano M. Haematological associations of Epstein-Barr virus infection. Baillieres Best Pract. Res. Clin. Haematol. 13, 199–214 (2000).
   PubMed Web of Science ®Google Scholar
• Hengge UR, Ruzicka T, Tyring SK et al. Update on Kaposi’s sarcoma and other HHV8 associated diseases. Part 2: pathogenesis, Castleman’s disease, and pleural effusion lymphoma. Lancet Infect. Dis. 2, 344–352 (2002).
   PubMed Web of Science ®Google Scholar
• Li YX, Coucke PA, Li JY et al. Primary non-Hodgkin’s lymphoma of the nasal cavity: prognostic significance of paranasal extension and the role of radiotherapy and chemotherapy. Cancer 83, 449–456 (1998).
   PubMed Web of Science ®Google Scholar
• Chan AT, Tao Q, Robertson KD et al. Azacitidine induces demethylation of the Epstein-Barr virus genome in tumors. J. Clin. Oncol. 22, 1373–1381 (2004).
   PubMed Web of Science ®Google Scholar
• Jaffe ES, Chan JK, Su IJ et al. Report of the workshop on nasal and related extranodal angiocentric T/natural killer cell lymphomas. definitions, differential diagnosis, and epidemiology. Am. J. Surg. Pathol. 20, 103–111 (1996).
   PubMed Web of Science ®Google Scholar
• Arber DA, Weiss LM, Albujar PF, Chen YY, Jaffe ES. Nasal lymphomas in Peru. High incidence of T-cell immunophenotype and Epstein-Barr virus infection. Am. J. Surg. Pathol. 17, 392–399 (1993).
   PubMed Web of Science ®Google Scholar
• Elenitoba-Johnson KS, Zarate-Osorno A, Meneses A et al. Cytotoxic granular protein expression, Epstein-Barr virus strain type, and latent membrane protein-1 oncogene deletions in nasal T-lymphocyte/natural killer cell lymphomas from Mexico. Mod. Pathol. 11, 754–761 (1998).
   PubMed Web of Science ®Google Scholar
• Nava VE, Jaffe ES. The pathology of NK-cell lymphomas and leukemias. Adv. Anat. Pathol. 12, 27–34 (2005).
   PubMed Web of Science ®Google Scholar
• Cheung MM, Chan JK, Lau WH, Ngan RK, Foo WW. Early stage nasal NK/T-cell lymphoma: clinical outcome, prognostic factors, and the effect of treatment modality. Int. J. Radiat. Oncol. Biol. Phys. 54, 182–190 (2002).
   PubMed Web of Science ®Google Scholar
• Cheung MM, Chan JK, Lau WH et al. Primary non-Hodgkin’s lymphoma of the nose and nasopharynx: clinical features, tumor immunophenotype, and treatment outcome in 113 patients. J. Clin. Oncol. 16, 70–77 (1998).
   PubMed Web of Science ®Google Scholar
• Harabuchi Y, Yamanaka N, Kataura A et al. Epstein-Barr virus in nasal T-cell lymphomas in patients with lethal midline granuloma. Lancet 335, 128–130 (1990).
   PubMed Web of Science ®Google Scholar
• Chan JK, Sin VC, Wong KF et al. Nonnasal lymphoma expressing the natural killer cell marker CD56: a clinicopathologic study of 49 cases of an uncommon aggressive neoplasm. Blood 89, 4501–4513 (1997).
   PubMed Web of Science ®Google Scholar
• van Gorp J, Weiping L, Jacobse K et al. Epstein-Barr virus in nasal T-cell lymphomas (polymorphic reticulosis/midline malignant reticulosis) in western China. J. Pathol. 173, 81–87 (1994).
   PubMed Web of Science ®Google Scholar
• Kanavaros P, Lescs MC, Briere J et al. Nasal T-cell lymphoma: a clinicopathologic entity associated with peculiar phenotype and with Epstein-Barr virus. Blood 81, 2688–2695 (1993).
   PubMed Web of Science ®Google Scholar
• Li Q, Spriggs MK, Kovats S et al. Epstein-Barr virus uses HLA class II as a cofactor for infection of B lymphocytes. J. Virol. 71, 4657–4662 (1997).
   PubMed Web of Science ®Google Scholar
• Haan KM, Kwok WW, Longnecker R, Speck P. Epstein-Barr virus entry utilizing HLA-DP or HLA-DQ as a coreceptor. J. Virol. 74, 2451–2454 (2000).
   PubMedGoogle Scholar
• Burkitt D. Determining the climatic limitations of a children’s cancer common in Africa. Br. Med. J. 5311, 1019–1023 (1962).
   Google Scholar
• de-The G, Geser A, Day NE et al. Epidemiological evidence for causal relationship between Epstein-Barr virus and Burkitt’s lymphoma from Ugandan prospective study. Nature 274, 756–761 (1978).
   PubMed Web of Science ®Google Scholar
• Epstein MA, Achong BG, Barr YM. Virus particles in cultured lymphoblasts from Burkitt’s lymphoma. Lancet 15, 702–703 (1964).
   Web of Science ®Google Scholar
• Hamilton-Dutoit SJ, Raphael M, Audouin J et al. In situ demonstration of Epstein-Barr virus small RNAs (EBER 1) in acquired immunodeficiency syndrome-related lymphomas: correlation with tumor morphology and primary site. Blood 82, 619–624 (1993).
   PubMed Web of Science ®Google Scholar
• Raab-Traub N, Flynn K. The structure of the termini of the Epstein-Barr virus as a marker of clonal cellular proliferation. Cell 47, 883–889 (1986).
   PubMed Web of Science ®Google Scholar
• Anwar N, Kingma DW, Bloch AR et al. The investigation of Epstein-Barr viral sequences in 41 cases of Burkitt’s lymphoma from Egypt: epidemiologic correlations. Cancer 76, 1245–1252 (1995).
   PubMed Web of Science ®Google Scholar
• Blum KA, Lozanski G, Byrd JC. Adult Burkitt leukemia and lymphoma. Blood 104, 3009–3020 (2004).
   PubMed Web of Science ®Google Scholar
• Khanna R, Moss D, Gandhi MK. Applications of emerging immunotherapeutic strategies for Epstein-Barr virus-associated malignancies. Nature Clin. Pract. Oncol. 2, 138–149 (2005).
   PubMedGoogle Scholar
• Sample J, Brooks L, Sample C et al. Restricted Epstein-Barr virus protein expression in Burkitt lymphoma is due to a different Epstein-Barr nuclear antigen 1 transcriptional initiation site. Proc. Natl Acad. Sci. USA 88, 6343–6347 (1991).
   PubMed Web of Science ®Google Scholar
• Niedobitek G, Agathanggelou A, Rowe M et al. Heterogeneous expression of Epstein-Barr virus latent proteins in endemic Burkitt’s lymphoma. Blood 86, 659–665 (1995).
   PubMed Web of Science ®Google Scholar
• Yoshioka M, Kikuta H, Ishiguro N, Ma X, Kobayashi K. Unique Epstein-Barr virus (EBV) latent gene expression, EBNA promoter usage and EBNA promoter methylation status in chronic active EBV infection. J. Gen. Virol. 84, 1133–1140 (2003).
   PubMed Web of Science ®Google Scholar
• Yates JL, Warren N, Sugden B. Stable replication of plasmids derived from Epstein-Barr virus in various mammalian cells. Nature 313, 812–815 (1985).
   PubMed Web of Science ®Google Scholar
• Wilson JB, Bell JL, Levine AJ. Expression of Epstein-Barr virus nuclear antigen-1 induces B cell neoplasia in transgenic mice. EMBO J. 15, 3117–3126 (1996).
   PubMed Web of Science ®Google Scholar
• Kang MS, Lu H, Yasui T et al. Epstein-Barr virus nuclear antigen 1 does not induce lymphoma in transgenic FVB mice. Proc. Natl Acad. Sci. USA 102, 820–825 (2005).
   PubMedGoogle Scholar
• Komano J, Maruo S, Kurozumi K, Oda T, Takada K. Oncogenic role of Epstein-Barr virus-encoded RNAs in Burkitt’s lymphoma cell line Akata. J. Virol. 73, 9827–9831 (1999).
   PubMed Web of Science ®Google Scholar
• Cohen JI, Wang F, Mannick J, Kieff E. Epstein-Barr virus nuclear protein 2 is a key determinant of lymphocyte transformation. Proc. Natl Acad. Sci. USA 86, 9558–9562 (1989).
   PubMed Web of Science ®Google Scholar
• Kelly G, Bell A, Rickinson A. Epstein-Barr virus-associated Burkitt lymphomagenesis selects for downregulation of the nuclear antigen EBNA2. Nature Med. 8, 1098–1104 (2002).
   PubMed Web of Science ®Google Scholar
• Yin Y, Manoury B, Fahraeus R. Self-inhibition of synthesis and antigen presentation by Epstein-Barr virus-encoded EBNA1. Science 301, 1371–1374 (2003).
   PubMed Web of Science ®Google Scholar
• Duraiswamy J, Bharadwaj M, Tellam J et al. Induction of therapeutic T-cell responses to subdominant tumor-associated viral oncogene after immunization with replication-incompetent polyepitope adenovirus vaccine. Cancer Res. 64, 1483–1489 (2004).
   PubMed Web of Science ®Google Scholar
• Lee SP, Brooks JM, Al-Jarrah H et al. CD8 T cell recognition of endogenously expressed epstein-barr virus nuclear antigen 1. J. Exp. Med. 199, 1409–1420 (2004).
   PubMedGoogle Scholar
• Tellam J, Sherritt M, Thomson S et al. Targeting of EBNA1 for rapid intracellular degradation overrides the inhibitory effects of the Gly-Ala repeat domain and restores CD8+ T cell recognition. J. Biol. Chem. 276, 33353–33360 (2001).
   PubMed Web of Science ®Google Scholar
• Khanna R, Burrows SR, Thomson SA et al. Class I processing-defective Burkitt’s lymphoma cells are recognized efficiently by CD4+ EBV-specific CTLs. J. Immunol. 158, 3619–3625 (1997).
   PubMed Web of Science ®Google Scholar
• Fu T, Voo KS, Wang RF. Critical role of EBNA1-specific CD4+ T cells in the control of mouse Burkitt lymphoma in vivo. J. Clin. Invest. 114, 542–550 (2004).
   PubMed Web of Science ®Google Scholar
• Paludan C, Schmid D, Landthaler M et al. Endogenous MHC class II processing of a viral nuclear antigen after autophagy. Science 307, 593–596 (2005).
   PubMed Web of Science ®Google Scholar
• Rea D, Delecluse HJ, Hamilton-Dutoit SJ et al. Epstein-Barr virus latent and replicative gene expression in post-transplant lymphoproliferative disorders and AIDS-related non-Hodgkin’s lymphomas. French Study Group of Pathology for HIV-associated Tumors. Ann. Oncol. 5(Suppl. 1), 113–116 (1994).
   PubMed Web of Science ®Google Scholar
• Meijer E, Dekker AW, Weersink AJ, Rozenberg-Arska M, Verdonck LF. Prevention and treatment of Epstein-Barr virus-associated lymphoproliferative disorders in recipients of bone marrow and solid organ transplants. Br. J. Haematol. 119, 596–607 (2002).
   PubMed Web of Science ®Google Scholar
• Paya CV, Fung JJ, Nalesnik MA et al. Epstein-Barr virus-induced post-transplant lymphoproliferative disorders. ASTS/ASTP EBV-PTLD Task Force and The Mayo Clinic Organized International Consensus Development Meeting. Transplantation 68, 1517–1525 (1999).
   PubMed Web of Science ®Google Scholar
• Cesarman E, Chadburn A, Liu YF, Migliazza A, Dalla-Favera R, Knowles DM. BCL-6 gene mutations in post-transplantation lymphoproliferative disorders predict response to therapy and clinical outcome. Blood 92, 2294–2302 (1998).
   PubMed Web of Science ®Google Scholar
• Finn L, Reyes J, Bueno J, Yunis E. Epstein-Barr virus infections in children after transplantation of the small intestine. Am. J. Surg. Pathol. 22, 299–309 (1998).
   PubMed Web of Science ®Google Scholar
• Curtis RE, Travis LB, Rowlings PA et al. Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study. Blood 94, 2208–2216 (1999).
   PubMed Web of Science ®Google Scholar
• Gandhi MK, Khanna R. Human cytomegalovirus: clinical aspects, immune regulation, and emerging treatments. Lancet Infect. Dis. 4, 725–738 (2004).
   PubMed Web of Science ®Google Scholar
• Hale G, Waldmann H. Risks of developing Epstein-Barr virus-related lymphoproliferative disorders after T-cell-depleted marrow transplants. CAMPATH Users. Blood 91, 3079–3083 (1998).
   PubMed Web of Science ®Google Scholar
• Opelz G, Henderson R. Incidence of non-Hodgkin lymphoma in kidney and heart transplant recipients. Lancet 342, 1514–1516 (1993).
   PubMed Web of Science ®Google Scholar
• Wagner HJ, Wessel M, Jabs W et al. Patients at risk for development of post-transplant lymphoproliferative disorder: plasma versus peripheral blood mononuclear cells as material for quantification of Epstein-Barr viral load by using real-time quantitative polymerase chain reaction. Transplantation 72, 1012–1019 (2001).
   PubMed Web of Science ®Google Scholar
• Tsai DE, Hardy CL, Tomaszewski JE. Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorder: analysis of prognostic variables and long-term follow-up of 42 adult patients. Transplantation 71, 1076–1088 (2001).
   PubMed Web of Science ®Google Scholar
• Herzig KA, Juffs HG, Norris D et al. A single-centre experience of post-renal transplant lymphoproliferative disorder. Transpl. Int. 16, 529–536 (2003).
   PubMedGoogle Scholar
• Milpied N, Vasseur B, Parquet N et al. Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: a retrospective analysis on 32 patients. Ann. Oncol. 11(Suppl. 1), 113–116 (2000).
   PubMed Web of Science ®Google Scholar
• Savoldo B, Rooney CM, Quiros-Tejeira RE et al. Cellular immunity to epstein-barr virus in liver transplant recipients treated with rituximab for post-transplant lymphoproliferative disease. Am. J. Transplant. 5, 566–572 (2005).
   PubMed Web of Science ®Google Scholar
• Starzl TE, Nalesnik MA, Porter KA et al. Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet 1, 583–587 (1984).
   PubMed Web of Science ®Google Scholar
• Hanto DW, Frizzera G, Gajl-Peczalska KJ, Simmons RL. Epstein-Barr virus, immunodeficiency, and B cell lymphoproliferation. Transplantation 39, 461–472 (1985).
   PubMed Web of Science ®Google Scholar
• Mentzer SJ, Fingeroth J, Reilly JJ, Perrine SP, Faller DV. Arginine butyrate-induced susceptibility to ganciclovir in an Epstein-Barr-virus-associated lymphoma. Blood Cells Mol. Dis. 24, 114–123 (1998).
   PubMed Web of Science ®Google Scholar
• Feng WH, Hong G, Delecluse HJ, Kenney SC. Lytic induction therapy for Epstein-Barr virus-positive B-cell lymphomas. J. Virol. 78, 1893–1902 (2004).
   PubMed Web of Science ®Google Scholar
• Rooney CM, Smith CA, Ng CY et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood 92, 1549–1555 (1998).
   PubMed Web of Science ®Google Scholar
• Khanna R, Bell S, Sherritt M et al. Activation and adoptive transfer of Epstein-Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease. Proc. Natl Acad. Sci. USA 96, 10391–10396 (1999).
   PubMed Web of Science ®Google Scholar
• Comoli P, Labirio M, Basso S et al. Infusion of autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for prevention of EBV-related lymphoproliferative disorder in solid organ transplant recipients with evidence of active virus replication. Blood 99, 2592–2598 (2002).
   PubMed Web of Science ®Google Scholar
• Comoli P, Maccario R, Locatelli F et al. Treatment of EBV-related post-renal transplant lymphoproliferative disease with a tailored regimen including EBV-specific T cells. Am. J. Transplant. 5, 1415–1422 (2005).
   PubMed Web of Science ®Google Scholar
• Wilkie GM, Taylor C, Jones MM et al. Establishment and characterization of a bank of cytotoxic T lymphocytes for immunotherapy of Epstein-Barr virus-associated diseases. J. Immunother. 27, 309–316 (2004).
   PubMed Web of Science ®Google Scholar
• Wynn RF, Arkwright PD, Haque T et al. Treatment of Epstein-Barr-virus-associated primary CNS B cell lymphoma with allogeneic T-cell immunotherapy and stem-cell transplantation. Lancet Oncol. 6, 344–346 (2005).
   PubMed Web of Science ®Google Scholar
• Haque T, Wilkie GM, Taylor C et al. Treatment of Epstein-Barr-virus-positive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells. Lancet 360, 436–442 (2002).
   PubMed Web of Science ®Google Scholar
• Hakulinen T, Isomaki H, Knekt P. Rheumatoid arthritis and cancer studies based on linking nationwide registries in Finland. Am. J. Med. 78, 29–32 (1985).
   PubMed Web of Science ®Google Scholar
• Symmons DP. Neoplasms of the immune system in rheumatoid arthritis. Am. J. Med. 78, 22–28 (1985).
   PubMed Web of Science ®Google Scholar
• Georgescu L, Paget SA. Lymphoma in patients with rheumatoid arthritis: what is the evidence of a link with methotrexate? Drug Saf. 20, 475–487 (1999).
   PubMed Web of Science ®Google Scholar
• Moder KG, Tefferi A, Cohen MD, Menke DM, Luthra HS. Hematologic malignancies and the use of methotrexate in rheumatoid arthritis: a retrospective study. Am. J. Med. 99, 276–281 (1995).
   PubMed Web of Science ®Google Scholar
• Kremer JM. Safety, efficacy, and mortality in a long-term cohort of patients with rheumatoid arthritis taking methotrexate: follow-up after a mean of 13.3 years. Arthritis Rheum. 40, 984–985 (1997).
   PubMedGoogle Scholar
• Weinblatt ME, Maier AL, Fraser PA, Coblyn JS. Longterm prospective study of methotrexate in rheumatoid arthritis: conclusion after 132 months of therapy. J. Rheumatol. 25, 238–242 (1998).
   PubMed Web of Science ®Google Scholar
• Cockburn IT, Krupp P. The risk of neoplasms in patients treated with cyclosporine A. J. Autoimmun. 2, 723–731 (1989).
   PubMed Web of Science ®Google Scholar
• Mariette X, Cazals-Hatem D, Warszawki J, Liote F, Balandraud N, Sibilia J. Lymphomas in rheumatoid arthritis patients treated with methotrexate: a 3-year prospective study in France. Blood 99, 3909–3915 (2002).
   PubMed Web of Science ®Google Scholar
• Salloum E, Cooper DL, Howe G et al. Spontaneous regression of lymphoproliferative disorders in patients treated with methotrexate for rheumatoid arthritis and other rheumatic diseases. J. Clin. Oncol. 14, 1943–1949 (1996).
   PubMed Web of Science ®Google Scholar
• Kamel OW, van de Rijn M, Weiss LM et al. Brief report: reversible lymphomas associated with Epstein-Barr virus occurring during methotrexate therapy for rheumatoid arthritis and dermatomyositis. N. Engl. J. Med. 328, 1317–1321 (1993).
   PubMed Web of Science ®Google Scholar
• Kamel OW, Weiss LM, van de Rijn M, Colby TV, Kingma DW, Jaffe ES. Hodgkin’s disease and lymphoproliferations resembling Hodgkin’s disease in patients receiving long-term low-dose methotrexate therapy. Am. J. Surg. Pathol. 20, 1279–1287 (1996).
   PubMed Web of Science ®Google Scholar
• Feng WH, Cohen JI, Fischer S et al. Reactivation of latent Epstein-Barr virus by methotrexate: a potential contributor to methotrexate-associated lymphomas. J. Natl Cancer Inst. 96, 1691–1702 (2004).
   PubMed Web of Science ®Google Scholar
• Tosato G, Steinberg AD, Yarchoan R et al. Abnormally elevated frequency of Epstein-Barr virus-infected B cells in the blood of patients with rheumatoid arthritis. J. Clin. Invest. 73, 1789–1795 (1984).
   PubMed Web of Science ®Google Scholar
• Tosato G, Steinberg AD, Blaese RM. Defective EBV-specific suppressor T-cell function in rheumatoid arthritis. N. Engl. J. Med. 305, 1238–1243 (1981).
   PubMed Web of Science ®Google Scholar
• Wilson WH, Kingma DW, Raffeld M, Wittes RE, Jaffe ES. Association of lymphomatoid granulomatosis with Epstein-Barr viral infection of B lymphocytes and response to interferon-a 2b. Blood 87, 4531–4537 (1996).
   PubMed Web of Science ®Google Scholar
• Koss MN, Hochholzer L, Langloss JM, Wehunt WD, Lazarus AA, Nichols PW. Lymphomatoid granulomatosis: a clinicopathologic study of 42 patients. Pathology 18, 283–288 (1986).
   PubMed Web of Science ®Google Scholar
• Beaty MW, Toro J, Sorbara L et al. Cutaneous lymphomatoid granulomatosis: correlation of clinical and biologic features. Am. J. Surg. Pathol. 25, 1111–1120 (2001).
   PubMed Web of Science ®Google Scholar
• Katzenstein AL, Carrington CB, Liebow AA. Lymphomatoid granulomatosis: a clinicopathologic study of 152 cases. Cancer 43, 360–373 (1979).
   PubMed Web of Science ®Google Scholar
• McNiff JM, Cooper D, Howe G et al. Lymphomatoid granulomatosis of the skin and lung. An angiocentric T-cell-rich B-cell lymphoproliferative disorder. Arch. Dermatol. 132, 1464–1470 (1996).
   PubMed Web of Science ®Google Scholar
• Medeiros LJ, Peiper SC, Elwood L, Yano T, Raffeld M, Jaffe ES. Angiocentric immunoproliferative lesions: a molecular analysis of eight cases. Hum. Pathol. 22, 1150–1157 (1991).
   PubMed Web of Science ®Google Scholar
• Stein H, Delsol G, Pileri S et al. Hodgkin’s lymphoma. In: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Jaffe ES, Harris NL, Stein H, Vardiman JW (Eds). International Agency for Research on Cancer Press, Lyon, France, 238–253 (2001).
   Google Scholar
• Pileri SA, Ascani S, Leoncini L et al. Hodgkin’s lymphoma: the pathologist’s viewpoint. J. Clin. Pathol. 55, 162–176 (2002).
   PubMed Web of Science ®Google Scholar
• Timms JM, Bell A, Flavell JR et al. Target cells of Epstein-Barr-virus (EBV)-positive post-transplant lymphoproliferative disease: similarities to EBV-positive Hodgkin’s lymphoma. Lancet 361, 217–223 (2003).
   PubMed Web of Science ®Google Scholar
• Kuppers R, Klein U, Schwering I et al. Identification of Hodgkin and Reed-Sternberg cell-specific genes by gene expression profiling. J. Clin. Invest. 111, 529–537 (2003).
   PubMed Web of Science ®Google Scholar
• Gandhi MK, Tellam JT, Khanna R. Epstein-Barr virus-associated Hodgkin’s lymphoma. Br. J. Haematol. 125, 267–281 (2004).
   PubMed Web of Science ®Google Scholar
• Herbst H, Dallenbach F, Hummel M et al. Epstein-Barr virus latent membrane protein expression in Hodgkin and Reed-Sternberg cells. Proc. Natl Acad. Sci. USA 88, 4766–4770 (1991).
   PubMed Web of Science ®Google Scholar
• Jarrett RF, Gallagher A, Jones DB et al. Detection of Epstein-Barr virus genomes in Hodgkin’s disease: relation to age. J. Clin. Pathol. 44, 844–848 (1991).
   PubMed Web of Science ®Google Scholar
• Ambinder RF, Browning PJ, Lorenzana I et al. Epstein-Barr virus and childhood Hodgkin’s disease in Honduras and the United States. Blood 81, 462–467 (1993).
   PubMed Web of Science ®Google Scholar
• Pallesen G, Hamilton-Dutoit SJ, Rowe M, Young LS. Expression of Epstein-Barr virus latent gene products in tumour cells of Hodgkin’s disease. Lancet 337, 320–322 (1991).
   PubMed Web of Science ®Google Scholar
• Jarrett AF, Armstrong AA, Alexander E. Epidemiology of EBV and Hodgkin’s lymphoma. Ann. Oncol. 7(Suppl. 4), 5–10 (1996).
   PubMed Web of Science ®Google Scholar
• Jarrett RF, Stark GL, White J et al. Impact of tumour Epstein-Barr virus status on presenting features and outcome in age-defined subgroups of patients with classical Hodgkin lymphoma: a population-based study. Blood 106(7), 2444–2451 (2005).
   PubMed Web of Science ®Google Scholar
• Hjalgrim H, Askling J, Rostgaard K et al Characteristics of Hodgkin’s lymphoma after infectious mononucleosis. N. Engl. J. Med. 349, 1324–1332 (2003).
   PubMed Web of Science ®Google Scholar
• Kuppers R. B cells under influence: transformation of B cells by Epstein-Barr virus. Nature Rev. Immunol. 3, 801–812 (2003).
   PubMed Web of Science ®Google Scholar
• Huen DS, Henderson SA, Croom-Carter D, Rowe M. The Epstein-Barr virus latent membrane protein-1 (LMP1) mediates activation of NF-κB and cell surface phenotype via two effector regions in its carboxy-terminal cytoplasmic domain. Oncogene 10, 549–560 (1995).
   PubMed Web of Science ®Google Scholar
• Bargou RC, Emmerich F, Krappmann D et al. Constitutive nuclear factor-κB-RelA activation is required for proliferation and survival of Hodgkin’s disease tumor cells. J. Clin. Invest. 100, 2961–2969 (1997).
   PubMed Web of Science ®Google Scholar
• Krappmann D, Emmerich F, Kordes U, Scharschmidt E, Dorken B, Scheidereit C. Molecular mechanisms of constitutive NF-κB/Rel activation in Hodgkin/Reed-Sternberg cells. Oncogene 18, 943–953 (1999).
   PubMed Web of Science ®Google Scholar
• Devergne O, Hatzivassiliou E, Izumi KM et al. Association of TRAF1, TRAF2, and TRAF3 with an Epstein-Barr virus LMP1 domain important for B-lymphocyte transformation: role in NF-κB activation. Mol. Cell. Biol. 16, 7098–7108 (1996).
   PubMed Web of Science ®Google Scholar
• Asso-Bonnet M, Feuillard J, Ferreira V et al. Relationship between IκBα constitutive expression, TNFα synthesis, and apoptosis in EBV-infected lymphoblastoid cells. Oncogene 17, 1607–1615 (1998).
   PubMedGoogle Scholar
• Portis T, Dyck P, Longnecker R. Epstein-Barr virus (EBV) LMP2A induces alterations in gene transcription similar to those observed in Reed-Sternberg cells of Hodgkin’s lymphoma. Blood 102(12), 4166–4178 (2003).
   PubMed Web of Science ®Google Scholar
• Portis T, Longnecker R. Epstein-Barr virus LMP2A interferes with global transcription factor regulation when expressed during B-lymphocyte development. J. Virol. 77, 105–114 (2003).
   PubMed Web of Science ®Google Scholar
• Diepstra A, Niens M, Vellenga E et al. Association with HLA class I in Epstein-Barr-virus-positive and with HLA class III in Epstein-Barr-virus-negative Hodgkin’s lymphoma. Lancet 365, 2216–2224 (2005).
   PubMed Web of Science ®Google Scholar
• Maggio E, van den Berg A, Diepstra A, Kluiver J, Visser L, Poppema S. Chemokines, cytokines and their receptors in Hodgkin’s lymphoma cell lines and tissues. Ann. Oncol. 13(Suppl. 1), 52–56 (2002).
   PubMed Web of Science ®Google Scholar
• Bollard CM, Aguilar L, Straathof KC et al. Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin’s disease. J. Exp. Med. 200, 1623–1633 (2004).
   PubMed Web of Science ®Google Scholar
• Duraiswamy J, Sherritt M, Thomson S et al. Therapeutic LMP1 polyepitope vaccine for EBV-associated Hodgkin disease and nasopharyngeal carcinoma. Blood 101, 3150–3156 (2003).
   PubMed Web of Science ®Google Scholar
• Gallagher A, Armstrong AA, MacKenzie J et al. Detection of Epstein-Barr virus (EBV) genomes in the serum of patients with EBV-associated Hodgkin’s disease. Int. J. Cancer 84, 442–448 (1999).
   PubMed Web of Science ®Google Scholar
• Kornacker M, Jox A, Vockerodt M et al. Detection of a Hodgkin/Reed-Sternberg cell specific immunoglobulin gene rearrangement in the serum DNA of a patient with Hodgkin’s disease. Br. J. Haematol. 106, 528–531 (1999).
   PubMedGoogle Scholar